Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) held its first Annual Scientific Advisory Board (SAB) meeting, assembling eight leading experts in psychiatry, addiction research, and metabolic disorders. The meeting focused on their lead candidate MEAI (5-Methoxy-2-aminoindane), currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD).
The SAB reviewed MEAI's potential advantages over GLP-1 therapies and its applications for obesity, metabolic syndrome, and veteran mental health. The company's intellectual property portfolio includes 31 granted patents worldwide. The advisory board's insights will guide Clearmind's development strategy for psychedelic-derived therapies.
Clearmind Medicine (Nasdaq: CMND) has secured a securities purchase agreement with institutional investors for convertible promissory notes worth up to $10 million. The initial closing includes notes worth $555,556 for a purchase price of $500,000, with an additional $1.94 million to be issued following SEC registration.
The agreement allows Clearmind to request additional note purchases of up to $2.5 million per quarter, totaling $7.5 million. The notes will be issued at 90% of principal value, carrying a 4% interest rate (14% upon default), with repayment in 10 monthly installments starting 18 months after issuance. The notes are convertible into common shares at a variable price not below $0.20.
Clearmind Medicine (Nasdaq: CMND) announced the publication of an international patent application for a novel combination therapy targeting obesity and metabolic syndrome. The patent, filed under the Patent Cooperation Treaty (PCT), covers the combination of Clearmind's MEAI compound with SciSparc's PEA compound.
The therapy aims to address metabolic syndrome, which affects up to one-third of U.S. adults, combining MEAI's pharmacological profile with PEA's anti-inflammatory and neuroprotective properties. This development is part of a broader collaboration between Clearmind and SciSparc that has generated 13 patent families across multiple jurisdictions including the United States, Europe, and China.
Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD). This approval follows FDA IND clearance and enables patient enrollment at the Jerusalem-based facility.
The multinational, multi-center trial will be conducted at several prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. The study aims to evaluate CMND-100's safety, tolerability, pharmacokinetic profile, and preliminary efficacy in reducing alcohol cravings and consumption in AUD patients.
The trial addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO data.
Clearmind Medicine (Nasdaq: CMND) has filed an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy using MEAI and Palmitoylethanolamide (PEA). The therapy targets obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
The company is developing this treatment in collaboration with SciSparc Ltd. (Nasdaq: SPRC). The therapy aims to address significant global health challenges, with obesity affecting over 890 million people worldwide and non-alcoholic fatty liver disease (NAFLD) impacting more than 30% of the global adult population.
Clearmind Medicine (Nasdaq: CMND) has successfully completed site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial of CMND-100, a novel oral drug candidate for Alcohol Use Disorder (AUD). The trial is being conducted across multiple prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Israeli medical centers.
The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing early efficacy signals in reducing alcohol cravings and consumption. The drug candidate utilizes 5-methoxy-2-aminoindane (MEAI) to potentially treat AUD, which currently affects millions globally and causes 2.6 million deaths annually.
Clearmind Medicine (Nasdaq: CMND) has expanded its Phase I/IIa clinical trial for CMND-100, its MEAI-based oral treatment for Alcohol Use Disorder (AUD). The company has activated a new clinical site at Johns Hopkins University School of Medicine and enrolled its first participant there.
The trial aims to evaluate safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing preliminary efficacy in reducing alcohol cravings and consumption. This expansion follows the recent enrollment of the first participant at Yale School of Medicine, demonstrating momentum in the multinational, multicenter study.
Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) for its ongoing Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).
The trial, which recently began dosing its first participant, will be conducted at several prestigious institutions including Yale School of Medicine, Johns Hopkins University, and Hadassah-University Medical Center. At TASMC, the study will be led by Dr. David Zeltser, Director of Emergency Medicine Department.
The multinational, multi-center study aims to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile, while assessing its preliminary efficacy in reducing alcohol cravings and consumption in AUD patients. This development addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO.
Clearmind Medicine (Nasdaq: CMND) has achieved a significant milestone by dosing the first participant with CMND-100, its proprietary MEAI-based oral drug candidate, in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). This marks the first human administration of the company's novel treatment in a clinical setting.
The multinational, multicenter trial is being conducted at prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah-University Medical Center. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing its preliminary efficacy in reducing alcohol cravings and consumption.
This development follows the company's June 5, 2025 announcement of the first participant enrollment. The trial will include both single- and multiple-dose studies to establish safety and optimal dosing parameters.
Clearmind Medicine (Nasdaq: CMND) announced the expansion of its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The company has added Hadassah-University Medical Center in Jerusalem as a new trial site, joining prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and IMCA.
The trial aims to evaluate safety, tolerability, and pharmacokinetics of CMND-100, while exploring its potential to reduce alcohol cravings. The expansion targets the global AUD market affecting over 280 million people, representing a multibillion-dollar opportunity given current limited treatment options.